The Role of Cognitive Therapy in Irritable Bowel Syndrome by Abadi, Ariane
Abstract
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder 
associated with abdominal pain and bowel movement issues. Treatment 
involves antispasmodics and antidiarrheals, as well as dietary 
manipulation. These interventions do not always provide adequate relief, 
pose considerable costs, and may be quite restrictive. Given the role of 
the brain-gut axis in IBS, cognitive therapy may be an essential part of 
treatment. As a result, this review analyzes the use of cognitive therapy (I) 
in adults (ages 18-75) with various types of IBS, and whether it provides 
similar or greater symptom relief (O) as compared to standard first line 
treatments (dietary manipulation and antispasmodics/antidiarrheals) (C). 
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Methods
A literature search was performed through PubMed and Google Scholar in 
November 2019. The seven articles selected consisted of randomized 
controlled trials and one case-control study and met the intended focuses 
such as types of treatment and sample population. The research designs, 
measures of outcome, and results were then contrasted and appraised. 
DiscussionResults
The Role of Cognitive Therapy in Irritable Bowel Syndrome
Some drawbacks to psychotherapy are inaccessibility, 
cost, time restraints, and lack of data on its efficacy 
compared to diet and medication. Subsequent trials must 
address these hindrances, as well as design weaknesses, 
to substantiate previous findings that suggest a 
combination of psychotherapy, diet, and medications 
offer the utmost benefit. Considering this, psychotherapy 
should be more widely implemented as standard IBS 
care. These therapies guide patients on symptom control 
by helping patients identify and reshape any negative or 
destructive thought patterns. They prevent the mind 
from going into overdrive with stress and thus triggering 
symptoms. 
Conclusion
Everitt H, Moss-Morris R, Sibelli A, et al. Management of irritable bowel syndrome in primary care: the results of an 
exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. 
BMC Gastroenterol. 2013;13:68.. doi:10.1186/1471-230X-13-68
Ø RCT of 135 participants comparing mebeverine (antispasmodic) and methylcellulose (bulking agent) vs placebo, and 
Regul8 (CBT self-management website)
Kennedy T, Chalder T, McCrone P, Darnley S, Knapp M., et al. Cognitive behavioural therapy in addition to 
antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial. Health Technol 
Assess 2006;10(19). doi: 10.3310/hta10190
Ø RCT of 149 subjects studying effects of CBT in conjunction with mebeverine vs. mebeverine alone
Lackner JM, Jaccard J, Keefer L, et al. Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for 
Refractory Irritable Bowel Syndrome [published correction appears in Gastroenterology. 2018 Oct;155(4):1281]. 
Gastroenterology. 2018;155(1):47–57. doi:10.1053/j.gastro.2018.03.063
Ø RCT of 436 participants comparing home-based CBT vs clinic-based CBT and patient education on IBS
Mahvi-Shirazi M, Fathi-Ashtiani A, Rasoolzade-Tabatabaei S-K, Amini M. Irritable bowel syndrome treatment: cognitive 
behavioral therapy versus medical treatment. Archives of Medical Science. 2012;1:123-129. 
doi:10.5114/aoms.2012.27292.
Ø Case-control study with 50 subjects comparing CBT with various pharmacotherapy vs. medication alone
Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed 
hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary 
Pharmacology & Therapeutics. 2016;44(5):447-459. doi:10.1111/apt.13706.
Ø RCT of 74 participants comparing hypnotherapy, low-FODMAP diet, and combination of these two 
Shahbazi K, Solati K, Hasanpour-Dehkordi A. Comparison of Hypnotherapy and Standard Medical Treatment Alone on 
Quality of Life in Patients with Irritable Bowel Syndrome: A Randomized Control Trial. J Clin Diagn Res. 
2016;10(5):OC01–OC4. doi:10.7860/JCDR/2016/17631.7713
Ø RCT of 60 patients comparing hypnotherapy and standard medical therapy alone, vs. combination 
Wittmann T, Paradowski L, Ducrotté P, Bueno L, Delestrain M-CA. Clinical trial: the efficacy of alverine 
citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - a randomized, double-
blind, placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2010;31(6):615-624. doi:10.1111/j.1365-
2036.2009.04216.x.
Ø RCT of 409 patients comparing alverine citrate with simethicone or matching placebo
Introduction
Study Symptom severity Quality of life Depression Anxiety
Everitt et al (2013) S (p = 0.037) at 6 weeks; 
difference diminished by 12 
weeks (NS) 
NS (p > 0.05) NS (p > 0.05) NS (p > 0.05)
Kennedy et al (2006) S at 1.5- and 3-month follow-
up (p < 0.0001), NS at 6- and 
12-month follow-up 
NM NS (p = 0.08) NS (p = 0.39)
Lackner et al (2018) S (p= 0.05) NM NM NM
Mahvi-Shirazi et al (2012) S (p < 0.001) at post-test level NM NS (p > 0.001) S (p < 0.001)
Peters et al (2016) S (p < 0.0001) S (p < 0.0001) NS* (p > 0.0001) NS
Shahbazi et al (2016) NM S (p <0.05) NM NM 
Wittmann et al (2010) S (p = 0.0001) NS* (p = 0.08) NS* (p > 0.001) NS* (p > 0.0001)
Key: S = significant; NS = not significant; NM = not measured, or not evaluated as specific outcome (such as HADS-D or HADS-A)     *Findings, although 
deemed statistically insignificant when comparing across all treatment groups, still demonstrated an upward trend (i.e., improvement in quality of life) or 
downward trend (decrease in depression, anxiety) 
• Theorized underlying mechanisms of IBS: abnormal 
motility, visceral hypersensitivity, intestinal 
inflammation, maladaptive psychosocial response
•Primarily afflicts women, often manifests in late teens 
to early twenties
•Global health prevalence of 10-15%
Overview
• Rome IV Criteria: abdominal pain present at least 1 
day/week, with 2 or more  of following: defecation 
issues, change in stool frequency, and change in stool 
appearance
•Constipation-predominant (IBS-C), Diarrhea-
predominant (IBS-D), mixed (IBS-M); varying degrees 
of symptom severity
•Associated with diminished quality of life, 
depression, and anxiety
Symptoms
•Mainstay treatment: antispasmodics, antidiarrheals, 
and dietary manipulation such as low-FODMAP diet 
(fermentable oligosaccharides, disaccharides, 
monosaccharides, polyols)
•Cognitive therapy and hypnotherapy may be helpful 
adjunct in treatment, given influence of visceral 
anxiety
Treatment
6/7 studies showed improvement in at least symptom 
severity, quality of life, anxiety, and/or depression at 
some point in the trials, as result of added psychotherapy 
or combination treatments
Although some results were not considered statistically 
significant,  they served as groundwork for future 
research and an opportunity to improve on limitations
Symptom severity outcome was 
consistently significant
Quality of life (QOL) was 
important variable to consider, 
given role of stress and IBS 
thought to trigger stress and 
























6 out of 7 studies were 
RCT, 1 was case-control 
study
Sample sizes: 50 to 400
Subjects: 18-75 years 
old
Mean age of 
population: 30-40 years













- Diversify sample 
population
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